Prothena Corporation PLC - PRX004 Phase 1 Study Results Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Prothena conference call about PRX004 Phase I study results. (Operator Instructions) Please be advised that today's conference may be recorded. (Operator Instructions) I would now hand the conference over to your speaker today, Ms. Ellen Rose, Head of Communication. Please go ahead, ma'am.
Thank you, and hello, everyone, and welcome to Prothena's investor conference call to review the positive results from the Phase I study of PRX004 in patients with ATTR amyloidosis. Please review the press release we issued earlier today, which is available on our website at prothena.com.
On today's call, Dr. Gene Kinney, our President and Chief Executive Officer, will provide introductory remarks. Dr. Wagner Zago, our Chief Scientific Officer, will then speak about ATTR amyloidosis, its underlying pathophysiology and key elements of PRX004's preclinical research.
Today, we will also be joined by 2 physicians with expertise in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
